Sunday, November 23, 2014
   
TEXT_SIZE

Mymetics Corporation is a US registered biotechnology company with its main office in Switzerland. Mymetics’ vision is to become the market leader in the development of new generation mucosal and virosomes based vaccines. The Company is focused on developing these innovative preventative vaccines using two key scientific approaches:

(i)    Virosomes as an effective adjuvant and a vaccine delivery method, and
(ii)    Innovative antigen design by generating mucosal antibodies.

With only 26 diseases addressed by vaccines, it is a well known fact that the world needs many more vaccines. By focusing on the two scientific approaches, Mymetics’ strategy is addressing two critical needs in developing effective vaccines:

(i)    The ability to build a first line of defense against viruses entering the blood stream by focusing on the mucosal layer.
(ii)    The development of a new vaccine delivery platform that does not use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine.

The Company is led by an international and experienced management team, with lifetime experience in vaccines and business management, which has achieved significant progress in developing and securing the rights and intellectual property to vaccines that use these two approaches. The team is supported by a very strong Scientific Advisory Board, consisting of world leading experts and key opinion leaders.

LATEST NEWS:

- SEPT. 29, 2014:  MYMETICS' PROMISING HIV VACCINE CANDIDATE OBTAINS FUNDING TO
                                   BEGIN STUDY AT TEXAS BIOMEDICAL RESEARCH INSTITUTE

- JULY 16, 2014:   MYMETICS SIGNS AGREEMENT TO MANUFACTURE VIROSOME BASED HER-VAXX 
                                   CANCER IMMUNOTHERAPY

- APR. 25, 2014:  WORLD MALARIA DAYS - link

- JAN. 6, 2014:      ASTELLAS TO FUND MYMETICS RSV VIROSOME VACCINE CANDIDATE THROUGH 
                                  INNOVATIVE LICENSE AND COLLABORATION AGREEMENT.

 

Recent Scientific Developments

Malaria

The vaccine, tested in in Tanzania on human by Mymetics and Pevion, has been well tolerated. Interim results show that antibodies against the two malaria parasite forms were present. Malaria Vaccine recent developments


HIV / AIDS

The pre-clinical trial results could not have been more convincing: The group that was vaccinated with Mymetics’ preventive HIV vaccine candidate showed 100% protection, while the non-vaccinated control group was fully infected. HIV/AIDS Vaccine recent developments


Influenza

After testing the intranasal influenza vaccine in a Phase I trial on 110 people, the vaccine was found to be safe and well tolerated. Influenza Vaccine recent developments

 


RSV

Mymetics' vaccine against RSV showed complete protection in its pre-clinical trial on mice and cotton rats. RSV Vaccine recent developments


Herpes Simplex Virus

Exploratory experiments were performed on mice in which the immunogenicity of HSV-1 virosomes is investigated, following injections through various routes (intra-muscular and intra-nasal). Herpes Vaccine recent developments


Virosome

Mymetics' laboratory in the Netherlands currently develops improved virosome technologies. Virosome recent developments